VivoSim Provides Financial and Listing Compliance Update
Rhea-AI Summary
VivoSim (Nasdaq: VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. Nasdaq’s Listing Qualifications Staff notified the company of compliance on August 4, 2026.
After filing its Form 10-K for the year ended March 31, 2026, VivoSim received a $5.0 million milestone payment and $1.0 million escrow release on July 22, 2026 related to its prior FXR program sale to Eli Lilly. On July 17, 2026, it completed a financing issuing pre-funded and common warrants at a combined purchase price of $0.85 per underlying share, generating $4.0 million gross and approximately $3.6 million net proceeds. These July events are not reflected in the March 31, 2026 audited statements or the upcoming June 30, 2026 Form 10-Q.
VivoSim reported cash of about $10.1 million as of August 3, 2026. Shares outstanding increased from 3,194,295 on June 30, 2026 to 13,390,789 on August 3, 2026, mainly from 9,896,718 warrant exercises in July. The company reiterated guidance for 500%+ revenue growth in fiscal 2027. All figures are preliminary and unaudited.
Positive
- Nasdaq equity compliance regained under Rule 5550(b)(1) as of August 4, 2026
- $6.0 million total July cash inflows from Eli Lilly FXR milestone and escrow release
- July 17, 2026 financing raised $4.0 million gross, about $3.6 million net
- Cash on hand of approximately $10.1 million as of August 3, 2026
- Company reiterates expectation of 500%+ revenue growth in fiscal year 2027
Negative
- Common shares outstanding rose from 3.19 million to 13.39 million between June 30 and August 3, 2026
- Approximately 9,896,718 shares issued in July 2026 upon warrant exercises, implying significant dilution
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | China commercial sales | Positive | -10.9% | First paid NAMkind programs launched through a China distributor |
| Jul 16 | Private placement | Negative | -28.1% | Warrants and shares priced at $0.85 for $4.0 million gross proceeds |
| Jul 15 | Milestone guidance | Positive | +2.2% | Eli Lilly milestone payment accompanied FY2027 revenue growth guidance |
| Jun 29 | Clinical model data | Positive | +2.9% | NAMkind liver and GI models presented comparative toxicity prediction data |
| Apr 28 | AI model launch | Positive | -0.7% | VitroSense platform reported gastrointestinal toxicity prediction accuracy |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive news aligned with gains in 2 of 4 positive events, while China sales and AI model news diverged.
Key Terms
new approach methodologies technical
pre-funded warrants financial
stockholders’ equity financial
form 10-k regulatory
generally accepted accounting principles financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of
Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the “Form 10-K”), the Company received a
The Company is drawing attention to these events because the timing of the events means they were not reflected in the Company’s audited financial statements for the year ended March 31, 2026 included in Form 10-K and will not be in the financial statements in the Company’s upcoming Quarterly Report on Form 10-Q filing for the period ended June 30, 2026.
As of August 3, 2026, the Company’s cash on hand was approximately
As of June 30, 2026, the Company had 3,194,295 shares of common stock outstanding, and as of August 3, 2026, the Company had 13,390,789 shares of common stock outstanding, which reflects 9,896,718 shares of common stock issued between July 15, 2026 and July 31, 2026 upon exercise of certain warrants to purchase common stock.
The Company reiterates its previously announced guidance that it anticipates
Preliminary Financial Information
The unaudited financial information presented in this press release is preliminary and may change. The Company undertakes no obligation to update or supplement the information provided in this press release. The preliminary financial information included in this press release reflects the Company’s current estimates based on information available as of the date hereof and has been prepared by the Company’s management. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with the Generally Accepted Accounting Principles and is not necessarily indicative of the results to be achieved for any future periods. This preliminary financial information could be impacted by the effects of financial closing procedures, final adjustments and other developments.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
